Both my son and I will go to NIH in April for research on Juvenile Spondylitis and Ankylosing Spondylitis.
FORBES: Xeljanz, A Cheaper-But-Expensive $25,000-A-Year Pfizer Pill For Rheumatoid Arthritis, Gets FDA Green Light
应用推荐
模块上移
模块下移
不移动